Journal Home
Search for

Volume 157, Issue 1, Pages 123-129 (15 January 2008)


View previous. 14 of 48 View next.

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy

Linda L. CarpenteraCorresponding Author Informationemail address, Lily Bayata, Francisco Morenob, Mitchel A. Klingc, Lawrence H. Pricea, Audrey R. Tyrkaa, Becky Kinkeadd, Michael J. Owensd, Charles B. Nemeroffd

Received 14 February 2006; received in revised form 9 April 2007; accepted 16 April 2007.

Abstract 

Recent preclinical and clinical research has demonstrated that the neuropeptide substance P (SP) plays a role in the central nervous system (CNS) response to stress, and perhaps in the etiology of major depression and/or anxiety disorders. The nature of this role, however, is poorly understood. A limited body of evidence suggests that in medication-free depressed patients, cerebrospinal fluid (CSF) concentrations of SP may be elevated relative to healthy controls. Two studies have shown that antidepressant treatment does not significantly change CSF concentrations of SP. Using standard lumbar puncture techniques, baseline CSF samples were obtained from 19 medication-free healthy controls and 19 medicated patients with treatment-resistant depression (TRD). Mean CSF SP concentration was significantly lower in TRD patients on psychotropic medications than in the group of healthy subjects. After 10–12 weeks of treatment with adjunct vagus nerve stimulation (VNS), CSF SP concentrations were not significantly changed. Low CSF SP may reflect a biological marker of the subtype of severe and chronic depression that is resistant to standard therapies.

a Mood Disorders Research Program, Butler Hospital, Brown University, Providence, RI, USA

b Department of Psychiatry, University of Arizona Health Sciences Center, Tucson, AZ, USA

c Departments of Psychiatry and Medicine, University of Maryland School of Medicine and Baltimore VA Medical Center, Baltimore, MD, USA

d Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

Corresponding Author InformationCorresponding author. Butler Hospital, 345 Blackstone Blvd., Providence, RI 02906, USA. Tel.: +1 401 455 6349; fax: +1 401 455 6534.

 This study was funded by Cyberonics, the manufacturer of the vagus nerve stimulation device. Drs. Linda Carpenter, Francisco Moreno, Mitchel Kling, Lawrence Price, and Charles Nemeroff have received consultant and/or lecture honoraria payments from Cyberonics.

PII: S0165-1781(07)00124-2

doi:10.1016/j.psychres.2007.04.016


View previous. 14 of 48 View next.